Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jCell (Famzeretcel) for Retinitis Pigmentosa
NCT06912633Phase 2Active, not recruiting
- Sponsor
- jCyte, Inc.
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of famzeretcel in retinitis pigmentosa (RP) (2 arms), sponsored by jCyte, Inc. Primary endpoint: Safety of Intravitreal Injection at 6 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
famzeretcel
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT06912633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912633.